These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 9437715

  • 1. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.
    Vertongen P, Schiffmann SN, Gourlet P, Robberecht P.
    Peptides; 1997; 18(10):1547-54. PubMed ID: 9437715
    [Abstract] [Full Text] [Related]

  • 2. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P, Vandermeers A, Van Rampelbergh J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.
    Ann N Y Acad Sci; 1998 Dec 11; 865():247-52. PubMed ID: 9928018
    [Abstract] [Full Text] [Related]

  • 3. Development of high affinity selective VIP1 receptor agonists.
    Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.
    Peptides; 1997 Dec 11; 18(10):1539-45. PubMed ID: 9437714
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Autoradiographic visualization of CNS receptors for vasoactive intestinal peptide.
    Shaffer MM, Moody TW.
    Peptides; 1986 Dec 11; 7(2):283-8. PubMed ID: 3016682
    [Abstract] [Full Text] [Related]

  • 7. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
    Juarranz MG, De Neef P, Robberecht P.
    Prostate; 1999 Sep 15; 41(1):1-6. PubMed ID: 10440869
    [Abstract] [Full Text] [Related]

  • 8. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
    Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.
    Peptides; 1997 Sep 15; 18(10):1555-60. PubMed ID: 9437716
    [Abstract] [Full Text] [Related]

  • 9. Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain.
    Martin JL, Dietl MM, Hof PR, Palacios JM, Magistretti PJ.
    Neuroscience; 1987 Nov 15; 23(2):539-65. PubMed ID: 3437978
    [Abstract] [Full Text] [Related]

  • 10. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.
    Vertongen P, Schiffmann SN, Gourlet P, Robberecht P.
    Ann N Y Acad Sci; 1998 Dec 11; 865():412-5. PubMed ID: 9928040
    [No Abstract] [Full Text] [Related]

  • 11. Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro.
    Reed HE, Meyer-Spasche A, Cutler DJ, Coen CW, Piggins HD.
    Eur J Neurosci; 2001 Feb 11; 13(4):839-43. PubMed ID: 11207820
    [Abstract] [Full Text] [Related]

  • 12. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
    Jiang X, Wang HY, Yu J, Ganea D.
    Ann N Y Acad Sci; 1998 Dec 11; 865():397-407. PubMed ID: 9928038
    [Abstract] [Full Text] [Related]

  • 13. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P, Rathé J, De Neef P, Cnudde J, Vandermeers-Piret MC, Waelbroeck M, Robberecht P.
    Eur J Pharmacol; 1998 Jul 31; 354(1):105-11. PubMed ID: 9726637
    [Abstract] [Full Text] [Related]

  • 14. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
    Gourlet P, Vandermeers-Piret MC, Rathé J, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.
    Eur J Pharmacol; 1998 May 01; 348(1):95-9. PubMed ID: 9650836
    [Abstract] [Full Text] [Related]

  • 15. Influence of selective VIP receptor agonists in the rat gastric fundus.
    Robberecht P, De Neef P, Lefebvre RA.
    Eur J Pharmacol; 1998 Oct 16; 359(1):77-80. PubMed ID: 9831296
    [Abstract] [Full Text] [Related]

  • 16. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
    Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.
    Mol Pharmacol; 1999 Dec 16; 56(6):1280-7. PubMed ID: 10570056
    [Abstract] [Full Text] [Related]

  • 17. Autoradiographic analysis of the distribution of vasoactive intestinal peptide binding sites in the vertebrate central nervous system: a phylogenetic study.
    Dietl MM, Hof PR, Martin JL, Magistretti PJ, Palacios JM.
    Brain Res; 1990 Jun 18; 520(1-2):14-26. PubMed ID: 2169952
    [Abstract] [Full Text] [Related]

  • 18. Effects of vasoactive intestinal polypeptide on neurones of the rat suprachiasmatic nuclei in vitro.
    Reed HE, Cutler DJ, Brown TM, Brown J, Coen CW, Piggins HD.
    J Neuroendocrinol; 2002 Aug 18; 14(8):639-46. PubMed ID: 12153466
    [Abstract] [Full Text] [Related]

  • 19. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
    Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.
    Peptides; 2000 Oct 18; 21(10):1543-9. PubMed ID: 11068102
    [Abstract] [Full Text] [Related]

  • 20. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Gen Comp Endocrinol; 2004 Jun 18; 137(2):187-95. PubMed ID: 15158130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.